Search
forLearn
5 / 801 resultslearn APISCALP™
learn PTD-DBM
learn ABN Complex
learn Ceramide AG
Research
5 / 100 results
research APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis simplex
A gene called APCDD1, which controls hair growth, is found to be faulty in a type of hair loss called hereditary hypotrichosis simplex.
research A Synonymous Polymorphism of APCDD1 Affects Translation Efficacy and is Associated with Androgenic Alopecia
A specific gene change in APCDD1 increases the risk of hair loss.
research A Synonymous Polymorphism of APCDD1 Affects Translation Efficacy and is Associated with Androgenic Alopecia
A certain gene variation can affect protein production and is linked to male pattern baldness.
research The Pathogenesis and Treatment Progress of Androgenic Alopecia
Future treatments for androgenic alopecia may focus on reactivating hair follicle stem cells and improving drug delivery.
research Biology and Genetics of Hair
The document concludes that understanding the genes and pathways involved in hair growth is crucial for developing treatments for hair diseases.
Community Join
5 / 1000+ resultscommunity DUPA VS. FAPD, which is more treatable? Which is worse?
DUPA is considered more treatable than FAPD, as FAPD involves scarring that prevents hair regrowth. The user has started treatment with oral dutasteride and minoxidil, hoping for better results than previous treatments.
community Starting Treatment for CCCA (scarring alopecia)
A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
community Treating my DUPA via controlling inflammation
The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.